A preliminary study of D-cycloserine treatment in Alzheimer's disease.
D-cycloserine is a partial agonist on the glycine site of the N-methyl-D-aspartate glutamate receptor. This double-blind crossover study of 15 mg D-cycloserine in Alzheimer's disease patients did not demonstrate clinical benefit. Higher medication dosage or long-term treatment may be required.
Tsai
G E
GE
Geriatric Neurobehavioral Clinic, Massachusetts General Hospital, Charlestown, USA. TSAIG@Helix.MGH.Harvard.EDU
Falk
W E
WE
Gunther
J
J
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D000704:Analysis of Variance; D003071:Cognition / Q000187:drug effects; D018592:Cross-Over Studies; D003523:Cycloserine / Q000627:therapeutic use*; D004311:Double-Blind Method; D018690:Excitatory Amino Acid Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010865:Pilot Projects; D016896:Treatment Outcome
D018690:Excitatory Amino Acid Agonists; D003523:Cycloserine